



ISOGENICA ANNOUNCES MULTI-TARGET MULTI-YEAR PARTNERSHIP WITH BIONTECH SE

**January 9th, 2020
Cambridge, UK**

Isogenica Ltd., a leader in the use of synthetic biology and *in vitro* display for the discovery and optimisation of novel single domain biotherapeutics, today announced it has entered into a multi-target, multi-year collaboration and license agreement with BioNTech SE (“BioNTech”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases.

Isogenica will use its proprietary LlamdA™ library and protein engineering expertise to discover and format single-domain LlamdA™ biotherapeutics against targets nominated by BioNTech. Isogenica has also granted BioNTech access to the LlamdA™ library for internal discovery work to build a pipeline of immune-oncology assets spanning multiple modalities including cell therapies, antibody-drug conjugates and antibody therapeutics. A steering committee comprising senior representatives of both companies will oversee the collaborative research.

“Isogenica’s collaboration with BioNTech is a great example of two companies with complimentary expertise and technologies coming together to accelerate the development of novel therapeutics” said Dr Emma Sceats, CEO of Isogenica. “Pairing LlamdA™ single domain antibodies with the full range of therapeutic modalities BioNTech brings to the collaboration promises to be an efficient and cost-effective means to develop individualized immunotherapies for patients”.

Under the terms of the multimillion-pound agreement, Isogenica is eligible to receive an upfront payment, research funding and licence fees, as well as preclinical, clinical and sales milestones on LlamdA™ antibody-based therapeutics deriving from the collaboration.

ENDS



Notes to Editors:

Emma Sceats, CEO, Isogenica

About Isogenica

Isogenica is an antibody discovery biotechnology company specializing in single-domain antibody therapeutics. These small format antibodies can be readily incorporated into gene and cell therapies, antibody-drug conjugates and bi- and multi-specific antibody therapeutics making them a highly versatile platform for drug development. The company's fully synthetic single domain library, LlamdA™, is designed from the DNA up, to eliminate liabilities and improve the biophysical traits of library antibodies. Combined with CIS Display, Isogenica's proprietary antibody display platform which enables the full diversity of the company's massive libraries to be displayed, the company has a unique and proven engine for therapeutic antibody discovery and development. Working in collaboration with biopharmaceutical partners over the last decade the company has developed a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.

For more information, visit: www.isogenica.com

Contact:

Mandeep Sehmi, Business Development

T: +44 1799 533 680

E: mandeep.sehmi@isogenica.com

